Introduction: The study aims to identify candidates who can be managed conservatively after the first episode of spontaneous painful acute urinary retention (AUR). Methods: A total of 20 patients with primary spontaneous painful AUR were prospectively included in the study. Twenty-four hours after AUR, the catheter was removed. When residual urinary volume was <100 ml, patients were referred without catheter, when residual urinary volume was ≥100 ml, the catheter was replaced and removed again at day 4, 7 or 10 after AUR, respectively. Receiver operating characteristic curves, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated to assess predictors for successful catheter removal. Results: Thirteen out of 20 (65%) patients had a successful catheter removal until day 10 after AUR. Among them 12 of 13 (93.2%) had a successful catheter removal until day 4 of AUR. Hydronephrosis urinary volume and Qmax at the time of AUR were significant numeric predictors for failure of successful catheter removal. In addition, we calculated a prediction model combing age + prostate volume + urinary volume + Qmax that highly predicts successful catheter removal (sensitivity 100%, specificity 69%, PPV 64%, NPV 100%). Conclusion: We found for the first time a significant association between hydronephrosis and successful catheter removal. Successful catheter removal until day 4 after AUR can safely be managed without immediate transurethral resection of the prostate.

Keywords:
Acute urinary retention, Predictive values for catheter removal, Prostate, Transurethral resection of the prostate
1.
Emberton M, Anson K: Acute urinary retention in men: an age old problem. BMJ 1999;318:921-925.
2.
Engström G, Henningsohn L, Steineck G, et al: Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract. BJU Int 2005;95:810-815.
3.
Parsons JK, Mougey J, Lambert L, et al: Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009;104:63-68.
4.
Fenter TC, Naslund MJ, Shah MB, et al: The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care 2006;12(4 suppl):S90-S98.
5.
Oelke M, Bachmann A, Descazeaud A, et al: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118-140.
6.
Chen JS, Chang CH, Yang WH, et al: Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study. BJU Int 2012;110:E896-E901.
7.
Emberton M, Fitzpatrick JM: The Reten-World survey of the management of acute urinary retention: preliminary results. BJU Int 2008;101(suppl 3):27-32.
8.
Manikandan R, Srirangam SJ, O'Reilly PH, et al: Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey. BJU Int 2004;93:84-88.
9.
Fitzpatrick JM, Desgrandchamps F, Adjali K, et al: Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia. BJU Int 2012;109:88-95.
10.
Agrawal MS, Yadav A, Yadav H, et al: A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. Indian J Urol 2009;25:474-478.
11.
Lucas MG, Stephenson TP, Nargund V: Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int 2005;95:354-357.
12.
Pfefferkorn U, Lea S, Moldenhauer J, et al: Antibiotic prophylaxis at urinary catheter removal prevents urinary tract infections: a prospective randomized trial. Ann Surg 2009;249:573-575.
13.
Tiong HY, Tibung MJ, Macalalag M, et al: Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. Urol Int 2009;83:44-48.
14.
Barry MJ, Fowler FJ Jr, O'Leary MP, et al: The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992;148:1549-1557; discussion 1564.
15.
DeLong ER, DeLong DM, Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-845.
16.
Boyle P, Gould AL, Roehrborn CG: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996;48:398-405.
17.
Park K, Kim SH, Ahn SG, et al: Analysis of the treatment of two types of acute urinary retention. Korean J Urol 2012;53:843-847.
18.
Bhomi KK, Bhattachan CL: Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia. Nepal Med Coll J 2011;13:178-181.
19.
Lee KS, Lim KH, Kim SJ, et al: Predictors of successful trial without catheter for postoperative urinary retention following non-urological surgery. Int Neurourol J 2011;15:158-165.
20.
Mahadik P, Vaddi SP, Godala CM, et al: Factors affecting trial without catheter for first spontaneous acute urinary retention. Int Neurourol J 2013;17:121-126.
21.
Mustonen S, Ala-Houhala IO, Vehkalahti P, et al: Kidney ultrasound and Doppler ultrasound findings during and after acute urinary retention. Eur J Ultrasound 2001;12:189-196.
22.
Kumar V, Marr C, Bhuvangiri A, et al: A prospective study of conservatively managed acute urinary retention: prostate size matters. BJU Int 2000;86:816-819.
23.
Daly P, Connolly S, Rogers E, et al: Management outcome of acute urinary retention: model of prediction. Urol Int 2009;83:39-43.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.